The Circ_0001367/miR-545-3p/LUZP1 Axis Regulates Cell Proliferation, Migration and Invasion in Glioma Cells

Xuchen Dong¹,²†, Peng Zhang¹,³†, Liang Liu¹†, Haoran Li¹, Shan Cheng¹, Suwen Li¹, Yuan Wang⁴, Chaoran Zheng⁴, Jun Dong¹* and Li Zhang⁴*

¹ Department of Neurosurgery, Second Affiliated Hospital of Soochow University, Suzhou, China, ² Medical College of Soochow University, Suzhou, China, ³ Department of Neurosurgery, Rugao Hospital Affiliated to Nantong University, Nantong, China, ⁴ College of Pharmaceutical Sciences, Soochow University, Suzhou, China

Glioma is the most common primary intracranial malignant tumour in adults. It has a high incidence and poses a serious threat to human health. Circular RNA is a hotspot of cancer research. In this study, we aimed to explore the role of circ_0001367 in gliomagenesis and the underlying mechanism. First, qRT-PCR was conducted, which showed that circ_0001367 level was downregulated in glioma tissues and cells. Next, gain-of-function and loss-of-function assays were performed, which indicated that circ_0001367 inhibited the proliferation, migration and invasion of glioma cells. Subsequent bioinformatics analysis, dual-luciferase reporter assays, RNA immunoprecipitation assays and cell function assays demonstrated that circ_0001367 inhibited the proliferation, migration and invasion of glioma cells by absorbing miR-545-3p and thereby regulating the expression of leucine zipper protein (LUZP1). Finally, an in vivo experiment was conducted, which demonstrated that circ_0001367 inhibited glioma growth in vivo by modulating miR-545-3p and LUZP1. Taken together, the results of this study demonstrate that the circ_0001367/miR-545-3p/LUZP1 axis may be a novel target for glioma therapy.

Keywords: circRNA, hsa_circ_0001367, miR-545-3p, LUZP1, glioma

INTRODUCTION

Glioma, which originates from the malignant transformation of glial cells, is one of the most common primary intracranial malignant tumors in adults (1, 2). It has a high incidence and poses a serious threat to human health. According to the pathological characteristics of gliomas, the World Health Organization (WHO) classifies gliomas into four grades (I, II, III and IV) (3). Almost all glioma patients diagnosed with high-grade glioma (HGG, comprising grades III and IV) experience recurrence after surgical resection, and the median survival time of HGG patients is only 30~39 weeks (4). Although advances have been made in surgical resection, radiotherapy, chemotherapy and targeted therapy in recent decades, the therapeutic effects of glioma treatment, especially glioblastoma treatment, remain unsatisfactory (5). To improve the efficacy of glioma treatment, a greater understanding of the molecular mechanisms of gliomagenesis is urgently needed.
Circular RNAs (circRNAs) are a kind of non-coding RNA that are widespread in mammals and exhibit a circular structure formed by covalent bonds (6, 7). Researchers formerly considered circRNAs to be junk RNAs that do not play roles in regulating biological activities (8, 9). However, support for the competing endogenous RNA (ceRNA) hypothesis proposed by Pandolfi et al. overturned this conventional view, and an increasing number of biological functions of circRNAs are gradually being explored (10). The circRNAs involved in human disease progression mainly exert their regulatory roles through the following six mechanisms: 1) by acting as sponges or traps of microRNA (miRNA); 2) by acting as sponges or traps of protein; 3) by affecting the transcription of downstream genes; 4) by affecting the variable splicing of target genes; 5) by regulating the translation function of target proteins; and 6) by participating in the epigenetic modification of target genes or proteins (11, 12). Numerous studies have reported that circRNAs play important roles in glioma. Liu et al. showed that circHIPK3 promotes glioma progression by targeting miR-124 (13), and Lou et al. reported that CDR1as inhibits gliomagenesis by disrupting the p53/MDM2 complex (14). Furthermore, Yang et al. reported that circ-FBXW7 encodes a functional protein to regulate glioma progression (15). However, the potential role of hsa_circ-0001367, a novel circRNA located on chromosome 3 (q27.1), in glioma has not been fully studied.

MicroRNAs (miRNAs) are a class of endogenous non-coding RNAs that regulate gene expression by mediating post-transcriptional silencing (16, 17). MiRNAs are widely involved in cell proliferation, cell differentiation, immune responses and other processes, and increasing evidence shows that miRNAs are important regulatory factors in disease progression (18, 19). Recent studies suggest that miRNAs can serve as targets of circRNAs and thereby participate in regulating cancer progression (20). An analysis via an online database (starBase, http://starbase.sysu.edu.cn/index.php) indicated that miR-545-3p may be a target of hsa_circ_0001367; however, the regulatory network containing miR-545-3p and hsa_circ_0001367 has not been reported.

Leucine zipper protein (LUZP1), predominantly expressed in brain, is reportedly involved in many diseases (21–23); however, its role in glioma remains unknown. Data from starBase indicate that the 3′-untranslated regions (3′-UTRs) of LUZP1 contain binding sites of miR-545-3p. In this study, we detected and correlated the expression of hsa_circ_0001367, miR-545-3p and LUZP1 in glioma tissues and cell lines. Moreover, function assays were performed to explore the mechanisms underlying the roles of hsa_circ_0001367/miR-545-3p/LUZP1 in gliomagenesis.

MATERIALS AND METHODS

Patient Enrollment

Glioma tissues and samples of corresponding adjacent normal brain tissue (36 paired samples) were obtained from patients diagnosed with glioma and admitted to Soochow University. The tissues were stored in liquid nitrogen immediately after excision. Written informed consent was obtained from all the glioma patients who participated in this study.

Cell Culture and Transfection

Human normal astrocytes were purchased from Jennio Biological Technology (Guangzhou, China). Human glioma cell lines U87, LN229, U251 and T98G were purchased from Procell (Wuhan, China). All the cell lines were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS, Gibco, USA). The cell lines were maintained in a humidified incubator (37°C and 5% CO2). Small interfering RNA (siRNA), miR-545-3p mimic, miR-545-3p inhibitor, overexpression plasmid (full-length sequence of circ_0001367 was cloned into pGL3-Basic Vector) and the corresponding negative controls used in this study were all synthesized by GenePharma (Shanghai, China). Once the cells reached approximately 80% confluence, they were transfected with synthesized oligonucleotides using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer’s protocol.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA was isolated from tissues and cells by using TRIzol (Invitrogen, USA). RNA was reverse transcribed into complementary DNA with the First Strand cDNA Synthesis Kit (MBI, Canada). SYBR Green Master Mix II (Takara, Japan) and the ABI 7900 system (Applied Biosystems, USA) were used to conduct qRT-PCR according to the manufacturers’ protocols. GAPDH and U6 were used as controls. The expression level of targets was determined by 2−∆∆Ct method. The following primers used in this study. Circ_0001367, 5′-TGG GTC TAT CTT CAG GGT CTG GA-3′ (forward) and 5′-GGA CAT CAT TTC ATT CCC AAG TA-3′ (reverse); miR-545-3p, 5′-TGG TCT ACG TCA GCA GGA AC-3′ (forward) and 5′-TGG TCT CAG CGG GTG GTG CAG-3′ (reverse); LUZP1, 5′-ATG ACC GAA TTT ACA AGC TAC-3′ (forward) and 5′-ATG ACC GAA TTT ACA AGC TAC-3′ (forward) and 5′-ATG CCAG TGA GCT TC CC-3′ (reverse); U6, 5′-CTC CCT TGC CCA GCA CA-3′ (forward) and 5′-AAC GCT TCA CGA ATT TGC GT-3′ (reverse).

Western Blot

Total protein was extracted from cells with the Total Protein Extraction Kit (KeyGEN BioTECH, Shanghai, China). Protein concentration was determined with the BCA Protein Assay Kit (KeyGEN BioTECH, Shanghai, China). Then, the proteins were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. After being blocked with blocking buffer for 10 min, the membranes were incubated with primary antibodies against LUZP1 (Proteintech, USA) and GAPDH (Proteintech, USA) overnight at 4°C. The membranes were then incubated with horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h. Image Quant LAS (GE, USA) was used for signal detection.

Dual-Luciferase Reporter Assay

The wild-type (WT) and mutant (MUT) sequences of circ_0001367 and miR-545-3p were synthesized and inserted into pmirGLO
vectors. Next, LN229 and T98G cells were transfected with miR-545-3p mimic or NC mimic along with WT or MUT reporter plasmids by using Lipofectamine 3000 (Invitrogen, USA). After 48 h, the luciferase activity was determined by the Dual-Luciferase Reporter Assay (Promega, USA).

Terminal Deoxyribonuclease Transferase dUTP Nick End Labeling (TUNEL) Staining

TUNEL staining was conducted by using the TUNEL Assay Kit (Beyotime, Shanghai, China). Cells were fixed with anhydrous ethanol and washed three times with PBS. Next, the cells were successively treated with Triton-X-100, terminal deoxynucleotidyl transferase (TdT), streptavidin HRP solution and DAB substrate according to the manufacturer’s protocol. The results were evaluated via microscope (Nikon, Japan).

RNase R Treatment

After being isolated from LN229 and T98G cells, total RNA was incubated with RNase R or the mock treatment for 30 min (37°C). Then, the expression of circ_0001367 and GAPDH was determined by qRT-PCR (24).

Actinomycin D Assay

Actinomycin D (2 mg/ml, APExBIO, USA) was added to culture medium to culture LN229 and T98G cells for 24 h. Next, the cells were harvested, and their expression of circ_0001367 and GAPDH was determined by qRT-PCR (24).

3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Assay

MTT assays were performed with an MTT kit (Beyotime, Shanghai, China). Cells were incubated with MTT solution (20 µl, 5 mg/ml) for 0, 24, 48 or 72 h. Then, dimethyl sulfoxide (DMSO, 4% 200 µl, Beyotime, Shanghai, China) was added to the cells. The absorbance at 490 nm was then determined with a microplate reader (Bio-Tek, Germany).

5-Ethynyl-20-Deoxyuridine (EdU) Assay

EdU assays were performed by using the EdU Cell Proliferation Kit with Alexa Fluor 488 (Beyotime, Shanghai, China). Cells were incubated with culture medium and EdU labelled for 4 h. After being fixed with anhydrous ethanol and treated with Triton-X-100, the cells were incubated with reaction buffer for 30 min and stained with DAPI for 5 min in darkness. The number of EdU-positive cells was measured with a fluorescence microscope (Olympus, Japan).

Transwell Assay

Cells were suspended in FBS-free culture medium (200 µl) and added to the upper chamber of Transwell inserts (Millipore, Germany). Medium (500 µl) containing 10% FBS was added to the lower chamber. After incubation in a humidified incubator (37°C and 5% CO₂) for 24 h, the non-migrated cells in the upper chamber were wiped with a wet cotton swab. The remaining cells were fixed in anhydrous ethanol and stained with 0.5% crystal violet. After being washed with PBS, the stained cells were imaged and counted under a microscope (Nikon, Japan). The invasion assay was conducted following the same steps described above for the migration assay except that the chambers were precoated with Matrigel (BD Biosciences, USA).

Tumor Xenograft Experiment

Nude mice aged 4-5 weeks were obtained from Shanghai SLAC Laboratory Animal Company (Shanghai, China). Stable cell lines LN229 overexpressing circ_0001367 or corresponding negative control were administered into the dorsal surface of the mice shoulder. Three weeks later, the tumors formed in the mice were excised. Tumor volume and weight were determined (volume = 0.5 × length × width²). In addition, the expression of circ_0001367, miR-545-3p and LUZP1 was determined by qRT-PCR, western blot or immunohistochemistry staining.

Statistical Analysis

The results of this study are presented as the mean ± standard deviation. SPSS software 19.0 (SPSS, USA) was used for statistical analysis. Student’s t-test was used for comparisons between groups. P <0.05 was considered statistically significant.

RESULTS

Hsa_circ_0001367 Was Downregulated in Glioma

qRT-PCR was used to measure circ_0001367 in the clinical samples. As shown in Figure 1A, circ_0001367 was significantly downregulated in glioma tissues compared with adjacent normal brain tissues (ANTSs). To determine whether circ_0001367 expression was associated with clinical features, Kaplan-Meier analysis was performed. The results indicated that patients in the low circ_0001367-expression group had a shorter survival time than those in the high-expression group (Figure 1B). In addition, we detected circ_0001367 expression in glioma cell lines and found that circ_0001367 was obviously downregulated in glioma cell lines compared with NAs (Figure 1C). RNase R digestion demonstrated that circ_0001367 was resistant to RNase R (Figure 1D). In addition, actinomycin D treatment showed that the circular structure of circ_0001367 was stable (Figure 1E). These findings suggested that circ_0001367 is involved in gliogenesis.

Hsa_circ_0001367 Inhibits the Proliferation, Migration and Invasion of Glioma Cells

To explore the role of circ_0001367 in gliomagenesis, circ_0001367 was upregulated or knocked down in LN229 and T98G cells by transfecting the cells with overexpression plasmid or small interfering RNA (siRNA). The transfection efficiency was verified by qRT-PCR (Figures S1A, B). MTT assays and EdU assays demonstrated that circ_0001367 overexpression obviously suppressed the proliferation of glioma cells. In contrast, the proliferation capacity of glioma cells was markedly promoted in circ_0001367-knockdown groups (Figures 2A-F). Furthermore, Transwell assays were performed to assess the effects of circ_0001367 on the migration and invasion of glioma cells. We
FIGURE 1 | Hsa_circ_0001367 was downregulated in glioma. (A) Expression of hsa_circ_0001367 in glioma tissues and adjacent non-neoplastic tissues (ANTs) detected by qRT-PCR. (B) Survival was compared between patients with high and low levels of hsa_circ_0001367 by Kaplan-Meier analysis. (C) Expression of hsa_circ_0001367 in glioma cell lines and normal human astrocytes (NHAs). (D) Expression of hsa_circ_0001367 and GAPDH in T98G and LN229 cells treated with RNase R or the mock treatment. (E) Expression of hsa_circ_0001367 and GAPDH in T98G and LN229 treated with Actinomycin D (Act D) or Mock. **P < 0.01.

FIGURE 2 | Hsa_circ_0001367 inhibits the proliferation, migration and invasion of glioma cells. (A–D) The effect of circ_0001367 on cell viability in T98G and LN229 cells was assessed with MTT assays. (E, F) EdU assays were used to evaluate the effect of circ_0001367 on the proliferation of T98G and LN229 cells. (G, H) Transwell assays were performed to analyse the effects of circ_0001367 on the migration and invasion of T98G and LN229 cells. *P < 0.05, **P < 0.01.
found that circ_0001367 overexpression significantly inhibited the migration and invasion ability of glioma cells, whereas circ_0001367 knockdown markedly enhanced the migration and invasion of glioma cells (Figures 2G, H). Taken together, these results suggest that circ_0001367 inhibits the proliferation, migration and invasion of glioma cells in vitro.

Hsa_circ_0001367 Act as a Sponge of miR-545-3p

The data obtained from starBase showed the presence of binding sites between circ_0001367 and miR-545-3p (Figure 3A). The luciferase reporter assay indicated that miR-545-3p was able to obviously reduce the luciferase activity of circ_0001367-WT cells; however, it had no pronounced effect in the circ_0001367-MUT group (Figure 3B). Furthermore, RIP assay verified that circ_0001367 and miR-545-3p were enriched in the anti-Ago2 group (Figures 3C, D). Next, we detected the expression of miR-545-3p in glioma tissues and cell lines. The results showed that miR-545-3p was upregulated in glioma tissues and cell lines compared with ANTs and NAs, respectively (Figures 3E, F). We also detected the level of miR-545-3p in circ_0001367-overexpression LN229 and T98G cells. The results demonstrated that miR-545-3p was downregulated when circ_0001367 was overexpressed (Figure 3G). These findings suggest that circ_0001367 acts as a sponge of miR-545-3p.

Hsa_circ_0001367 Suppresses Glioma Progression by Absorbing miR-545-3p

To investigate whether circ_0001367 exerts its function in LN229 and T98G cells by sponging miR-545-3p, function assays were conducted. The transfection efficiency of circ_0001367-overexpression plasmid and miR-545-3p mimics was verified by qRT-PCR (Figure S1C). The MTT assays and EdU assays demonstrated that circ_0001367 overexpression obviously decreased the proliferation of glioma cells and that this inhibitory effect could be reversed by miR-545-3p mimic (Figures 4A–D). Similarly, the Transwell assays showed that miR-545-3p mimic could reverse the inhibition of migration and invasion caused by circ_0001367 overexpression (Figures 4E, F). These results suggest that circ_0001367 suppresses the proliferation, migration and invasion of glioma cells by absorbing miR-545-3p.

LUZP1 Is the Direct Target of miR-545-3p

The data from starBase indicated that the 3'-UTR of LUZP1 contains sites that can bind to miR-545-3p (Figure 5A). The luciferase reporter assay indicated that miR-545-3p could reduce the luciferase activity of LUZP1-WT cells much more than that of LUZP1-MUT cells (Figure 5B). By searching the online database GEPIA, we found that LUZP1 was downregulated in glioma tissues (Figure 5C). Next, we detected LUZP1 expression in clinical samples by qRT-PCR. The results demonstrated that LUZP1 was downregulated in glioma tissues compared with ANTs (Figure 5D). Consistent with this finding, LUZP1 was downregulated in LN229 and T98G cells compared with NAs (Figures 5E, F). Furthermore, we detected LUZP1 expression in the cell models we constructed previously. qRT-PCR and western blot indicated that hsa_circ_0001367 overexpression could promote expression of LUZP1, meanwhile, miR-545-3p mimic could suppress expression of LUZP1 (Figures 5G–J). These findings indicate that LUZP1 is the direct target of miR-545-3p.
FIGURE 4 | Hsa_circ_0001367 suppresses glioma progression by absorbing miR-545-3p. (A, B) Cell proliferation was investigated by MTT assay after transfection. (C, D) Cell proliferation was tested by EdU assay after transfection. (E, F) Transwell assay was conducted to measure the migration and invasion capacity of T98G and LN229 cells after transfection. *P < 0.05, **P < 0.01.

FIGURE 5 | LUZP1 is the direct target of miR-545-3p. (A) The binding sites of miR-545-3p and LUZP1 predicted by starBase. (B) The relative luciferase activity in T98G and LN229 cells was detected by dual-luciferase reporter assay. (C) The expression of LUZP1 in the public database (GEPIA). (D) The expression of LUZP1 in clinical samples detected by qRT-PCR. (E, F) The expression of LUZP1 in glioma cell lines detected by qRT-PCR and western blot. (G, H) LUZP1 expression in T98G and LN229 which transfected with miR-NC or miR-545-3p detected by qRT-PCR and western blot. (I, J) LUZP1 expression in T98G and LN229 cells transfected with vector, circ_0001367, circ_0001367+miR-NC or circ_0001367+miR-545-3p was detected by qRT-PCR and western blot. *P < 0.05, **P < 0.01.
LUZP1 Downregulation Restored the Effect of miR-545-3p Knockdown or circ_0001367 Overexpression on Glioma Cells

To investigate whether LUZP1 is the functional target of miR-545-3p in LN229 and T98G cells, we constructed four cell models. The efficiency of miR-545-3p inhibitor and si-LUZP1 transfection was verified by qRT-PCR (Figure S1D). The MTT and EdU assays suggested that LUZP1 deletion could block the suppressive effect of miR-545-3p inhibitor on glioma proliferation (Figures 6A–D). Consistent with this finding, the Transwell assays showed that the migration and invasion ability of LN229 and T98G cells was impaired by miR-545-3p inhibitor, whereas LUZP1 deletion reversed this inhibitory effect (Figures 6E, F). In addition, function assays indicated that LUZP1 deletion could block the suppressive effect of circ_0001367 overexpression on glioma proliferation, migration and invasion (Figures 7A–F). These results suggested that LUZP1 downregulation restored the effect of miR-545-3p knockdown and circ_0001367 overexpression on glioma cells.

Hsa_circ_0001367 Inhibited Glioma Growth In Vivo

To evaluate the effect of circ_0001367 on glioma growth in vivo, LN229 cells transfected with circ_0001367-overexpression plasmid or corresponding negative control were subcutaneously injected into mice. Three weeks later, tumors had formed. Compared with those in the negative control group, the tumors formed in the circ_0001367-overexpression group were lower in weight and smaller in volume (Figures 8A–D). qRT-PCR showed that circ_0001367 was upregulated whereas miR-545-3p was downregulated in the tumors formed in the circ_0001367-overexpression group (Figure 8E). Furthermore, qRT-PCR and western blot revealed that LUZP1 was upregulated in the circ_0001367-overexpression group relative to the control group (Figures 8E, F). Furthermore, Ki-67 staining indicated that circ_0001367 overexpression decreased the proportion of Ki-67-positive cells (Figure 8G). TUNEL staining showed that more apoptosis occurred in the circ_0001367-overexpression group than in the control group (Figure 8H).

DISCUSSION

Glioma is the most common malignant tumor of the central nervous system. In the past 30 years, despite numerous studies on glioma pathogenesis, the prognosis of glioma patients has not improved significantly (25). Therefore, it is of great significance for the clinical diagnosis and treatment of glioma to focus on the pathogenesis of glioma.
FIGURE 7 | LUZP1 downregulation restored the effect of circ_0001367 overexpression on glioma cells. (A, B) The proliferation of cells transfected with si-LUZP1, circ_0001367 or si-LUZP1 plus circ_0001367 was tested by MTT assay. (C, D) The proliferation of cells transfected with si-LUZP1, circ_0001367 or si-LUZP1 plus circ_0001367 was tested by EdU assay. (E, F) Transwell assay was conducted to measure the migration and invasion capacity of cells which transfected with si-LUZP1, circ_0001367 or si-LUZP1 plus circ_0001367. *P < 0.05, **P < 0.01.

FIGURE 8 | Hsa_circ_0001367 inhibited glioma growth in vivo. (A, B) Tumour formation was examined in nude mice following the implantation of LN229 xenografts with vector or circ_0001367 overexpression. (C, D) The volume and weight of tumours formed in the nude mice. (E) The expression of circ_0001367, miR-545-3p and LUZP1 in the tumours formed in the nude mice was measured by qRT-PCR. (F) The expression of LUZP1 in the tumours formed in the nude mice was measured by western blotting. (G) Immunohistochemistry for Ki-67 in the tumours formed in the nude mice. (H) TUNEL staining of the tumours formed in the nude mice. *P < 0.01.
CircRNAs have become a hot topic in cancer research since the recent replacement of the traditional view of circRNAs as non-functional molecules with the understanding that they influence various cellular activities (9, 26). CircRNAs are not sensitive to nucleases, so it is more stable than the corresponding linear RNAs, which makes them a significant advantage as a new clinical diagnostic marker and target for therapy (27). Accumulating studies have shown that several circRNAs are closely associated with human cancers. For example, circ_0000039 has been found to be a biomarker of tissue differentiation in gastric cancer (28); circ_0000282 has been shown to be upregulated in osteosarcoma and associated with the proliferation of osteosarcoma cells (29); and circ_0026416 functions as an oncogene in colorectal cancer and may be a novel biomarker for diagnosis (30). In the present study, we found that circ_0001367 was significantly downregulated in glioma tissues and cells and that its expression level was negatively associated with the survival of glioma patients. The gain-of-function and loss-of-function assays revealed that circ_0001367 overexpression inhibits the proliferation, migration and invasion of glioma cells, whereas circ_0001367 silencing promotes these processes. These findings suggest that circ_0001367 acts as a suppressor in glioma.

It is currently theorized that circRNAs are mainly distributed in the cytoplasm and play a role in regulating tumor progression through the adsorption of miRNAs. For example, circ_0001785 can sponge miR-942 or miR-1200 to regulate breast cancer or osteosarcoma progression, respectively (31, 32); and circ_0000285 can absorb miR-409-3p, miR-197-3p and miR-599, thereby affecting the progression of cervical cancer and osteosarcoma (24, 33, 34). Analysis using an online database revealed 29 miRNAs that may serve as the target of circ_0001367. Among them, miR-545-3p aroused our great interest. MiR-545-3p dysregulation has been reported in diverse cancers. Shi et al. reported that miR-545-3p was downregulated in epithelial ovarian cancer (35); Hao et al. showed that miR-545-3p inhibits the proliferation and differentiation of osteoblasts (36); and Zhong et al. reported that miR-545-3p functions as a tumor suppressor in endometrial carcinoma (37). Furthermore, some studies indicate that miR-545-3p may be the target of circRNAs. Chen et al. reported that miR-545-3p can be sponged by circ_0007580 and is thus involved in non-small lung cancer progression (38); and Li et al. showed that circ_0072083 promotes non-small lung cancer progression by absorbing miR-545-3p (39). To date, the role of miR-545-3p in glioma and the associated circRNA-miRNA network have not been studied. In our study, employing a dual-luciferase reporter assay and RIP assay, we verified that miR-545-3p can be sponged by circ_0001367. In addition, function assays indicated that miR-545-3p can reverse the effects of circ_0001367 overexpression on glioma proliferation, migration and invasion. All of these findings suggest that circ_0001367 sponges miR-545-3p to regulate gliomagenesis.

Using an online database, we found that miR-545-3p directly targets LUZP1. LUZP1 is a regulator of primary cilia and actin cytoskeleton and has been reported to be associated with colorectal cancer, neural tube closure and Townes-Brocks syndrome (21–23); however, its role in glioma has not been studied. Herein, we showed that LUZP1 was significantly downregulated in glioma tissues and cells. Furthermore, function assays indicated that LUZP1 functions as a suppressor in glioma and is regulated by miR-545-3p.

In summary, our study revealed that circ_0001367 was markedly downregulated in glioma tissues and cells. In addition, it demonstrated that circ_0001367 suppresses the proliferation, migration and invasion of glioma cells by sponging miR-545-3p to regulate LUZP1. The circ_0001367/miR-545-3p/LUZP1 axis may be a novel target for glioma therapy.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT
The animal study was reviewed and approved by Ethics Committee of Soochow University.

AUTHOR CONTRIBUTIONS
XD conducted the cell assays and wrote the manuscript. PZ, HL, and CZ collected clinical samples and conducted the in vivo experiments. LL, SC, and SL analyzed the data, search literatures and prepared the figures. YW designed the experiments and edited the manuscript. LZ designed the experiments, supervised the research and reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This study was supported by Hui-Chun Chin and Tsung-Dao Lee Chinese Undergraduate Research Endowment (CURE); National Natural Sciences Foundation of China (82072798, 82073873, 81803616); Jiangsu province key research and development program: Social development project (BE2021653); Natural Science Foundation of Jiangsu Province, China (BK20201172), Key project of Jiangsu Health Commission (ZDB2020016); Research and Practice Innovation Program for Postgraduates in Jiangsu (SICX19_0183); School-level scientific research project of Jiangsu Health Vocational College (JKC202022).

Frontiers in Oncology | www.frontiersin.org November 2021 | Volume 11 | Article 7814719
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.781471/full#supplementary-material

REFERENCES

1. Huang H, Zhang W, Fang Y, Hong J, Su S, Lai X. Overall Survival Prediction for Gliomas Using a Novel Compound Approach. Front Oncol (2021) 11:724191. doi: 10.3389/fonc.2021.724191
2. Huang Q, Lian C, Dong Y, Zeng H, Liu B, Xu N, et al. SNP25 Inhibits Glioma Progression by Regulating Synapse Plasticity via GLS-Mediated Glutaminolysis. Front Oncol (2021) 11:698835. doi: 10.3389/fonc.2021.698835
3. Chang YZ, Li GZ, Pang B, Zhang KN, Zhang XH, Wang YZ, et al. Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. Front Cell Dev Biol (2020) 8:580464. doi: 10.3389/fcell.2020.580464
4. Xiao ZZ, Wang ZF, Lan T, Huang WH, Zhao YH, Ma C, et al. Carmustine for Gliomas Using a Novel Compound Approach. Front Oncol (2021) 11:703036. doi: 10.3389/fonc.2021.00703
5. Li X, Ding F, Gao J, Huang X, Su S, Lai X. Overall Survival Prediction for Gliomas Using a Novel Compound Approach. Front Oncol (2021) 11:724191. doi: 10.3389/fonc.2021.724191
6. Hu H, Zhang W, Fang Y, Hong J, Su S, Lai X. Overall Survival Prediction for Gliomas Using a Novel Compound Approach. Front Oncol (2021) 11:724191. doi: 10.3389/fonc.2021.724191
7. Taulli R, Loretelli C, Pandol...
35. Shi J, Xu X, Zhang D, Zhang J, Yang H, Li C, et al. Long Non-Coding RNA PTPRG-AS1 Promotes Cell Tumorigenicity in Epithelial Ovarian Cancer by Decoying microRNA-545-3p and Consequently Enhancing HDAC4 Expression. J Ovarian Res (2020) 13(1):127. doi: 10.1186/s13048-020-00723-7

36. Hao R, Wang B, Wang H, Huo Y, Lu Y. IncRNA TUG1 Promotes Proliferation and Differentiation of Osteoblasts by Regulating the miR-545-3p/CNR2 Axis. Braz J Med Biol Res (2020) 53(11):e9798. doi: 10.1590/1414-431X20209798

37. Zhong Y, Wang Y, Dang H, Wu X. LncRNA AFAP1-AS1 Contributes to the Progression of Endometrial Carcinoma by Regulating miR-545-3p/VEGFA Pathway. Mol Cell Probes (2020) 53:101606. doi: 10.1016/j.mcp.2020.101606

38. Chen S, Lu S, Yao Y, Chen J, Yang G, Tu L, et al. Downregulation of hsa_circ_0007580 Inhibits Non-Small Cell Lung Cancer Tumorigenesis by Reducing miR-545-3p Sponging. Aging (Albany NY) (2020) 12(14):14329–40. doi: 10.18632/aging.103472

39. Li H, Liu F, Qin W. Circ_0072083 Interference Enhances Growth-Inhibiting Effects of Cisplatin in Non-Small-Cell Lung Cancer Cells via miR-545-3p/CBL1 Axis. Cancer Cell Int (2020) 20:78. doi: 10.1186/s12935-020-1162-x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Dong, Zhang, Liu, Li, Cheng, Li, Wang, Zheng, Dong and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.